Ocular Therapeutix (OCUL) Quick Ratio: History & Chart

Ocular Therapeutix, Inc.(OCUL)

Biotechnology · Bedford, MA

$7.48+0.23 (+3.17%)

Delayed quote: Oct 6, 2026, 2:50 PM EDT

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Bedford, MA

325 employees

www.ocutx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pravin U. Dugel

View full financials

OCUL Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

13.03

QUICK RATIO (ACID-TEST) AVG TTM

12.18

QUICK RATIO (ACID-TEST) AVG 3Y

11.23

QUICK RATIO (ACID-TEST) AVG 5Y

9.39

QUICK RATIO (ACID-TEST) AVG 10Y

7.72

QUICK RATIO (ACID-TEST) AVG 15Y

N/A

QUICK RATIO (ACID-TEST) AVG 20Y

N/A

CURRENT VS TTM AVG

+6.99%

CURRENT VS 3Y AVG

+16.01%

CURRENT VS 5Y AVG

+38.81%

CURRENT VS 10Y AVG

+68.74%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

3.35

median of 871 covered companies

CURRENT VS SECTOR MEDIAN

+288.87%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Ocular Therapeutix, Inc. (OCUL)	$1.64B	13.03	12.18	11.23	9.39
Alphatec Holdings, Inc. (ATEC)vs ›	$1.63B	1.07	1.43	1.49	1.78
Septerna Inc (SEPN)vs ›	$1.63B	4.99	16.25	13.64	13.64
ANI Pharmaceuticals, Inc. (ANIP)vs ›	$1.62B	2.41	2.10	2.35	2.26
Omnicell, Inc. (OMCL)vs ›	$1.61B	1.43	1.22	1.59	1.63
Kestra Medical Technologies, Ltd. (KMTS)vs ›	$1.61B	4.69	5.42	2.91	3.12
uniQure N.V. (QURE)vs ›	$1.61B	10.01	10.09	8.76	10.27
Zenas BioPharma, Inc. (ZBIO)vs ›	$1.69B	9.93	5.91	4.26	4.26
Stoke Therapeutics, Inc. (STOK)vs ›	$1.57B	7.69	5.54	6.46	10.83
Personalis, Inc. (PSNL)vs ›	$1.70B	5.08	6.50	5.46	6.20

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Ocular Therapeutix, Inc. (OCUL)

$1.64B

13.03

12.18

11.23

9.39

Alphatec Holdings, Inc. (ATEC)vs ›

$1.63B

1.07

1.43

1.49

1.78

Septerna Inc (SEPN)vs ›

$1.63B

4.99

16.25

13.64

ANI Pharmaceuticals, Inc. (ANIP)vs ›

$1.62B

2.41

2.10

2.35

2.26

Omnicell, Inc. (OMCL)vs ›

$1.61B

1.43

1.22

1.59

1.63

Kestra Medical Technologies, Ltd. (KMTS)vs ›

$1.61B

4.69

5.42

2.91

3.12

uniQure N.V. (QURE)vs ›

$1.61B

10.01

10.09

8.76

10.27

Zenas BioPharma, Inc. (ZBIO)vs ›

$1.69B

9.93

5.91

4.26

Stoke Therapeutics, Inc. (STOK)vs ›

$1.57B

7.69

5.54

6.46

10.83

Personalis, Inc. (PSNL)vs ›

$1.70B

5.08

6.50

5.46

6.20

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Ocular Therapeutix, Inc. (OCUL)?

The quick ratio (acid-test) for OCUL stock is 13.03.

Is Ocular Therapeutix, Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 13.03 is 39% above its 5-year average of 9.39, around the middle of its 5-year range (3.04–21.29).

What is the TTM average quick ratio (acid-test) for Ocular Therapeutix, Inc. (OCUL)?

The TTM average quick ratio (acid-test) for OCUL stock is 12.18.

What is the 3Y average quick ratio (acid-test) for Ocular Therapeutix, Inc. (OCUL)?

The 3Y average quick ratio (acid-test) for OCUL stock is 11.23.

What is the 5Y average quick ratio (acid-test) for Ocular Therapeutix, Inc. (OCUL)?

The 5Y average quick ratio (acid-test) for OCUL stock is 9.39.

What is the 10Y average quick ratio (acid-test) for Ocular Therapeutix, Inc. (OCUL)?

The 10Y average quick ratio (acid-test) for OCUL stock is 7.72.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	13.03
2026-03-31	14.73
2025-12-31	15.32
2025-09-30	7.78
2025-06-30	10.02
2025-03-31	10.14
2024-12-31	10.59
2024-09-30	12.94
2024-06-30	16.55
2024-03-31	21.29
2023-12-31	6.59
2023-09-30	3.96
2023-06-30	3.04
2023-03-31	3.53
2022-12-31	4.07
2022-09-30	4.92
2022-06-30	6.08
2022-03-31	7.23
2021-12-31	7.22
2021-09-30	8.06
2021-06-30	10.00
2021-03-31	8.27
2020-12-31	9.19
2020-09-30	3.53
2020-06-30	6.46
2020-03-31	4.86
2019-12-31	4.92
2019-09-30	6.25
2019-06-30	6.39
2019-03-31	9.16
2018-12-31	6.11
2018-09-30	4.34
2018-06-30	4.90
2018-03-31	4.89
2017-12-31	3.22
2017-09-30	4.78
2017-06-30	5.20
2017-03-31	9.61
2016-12-31	8.41
2016-09-30	9.30
2016-06-30	13.21
2016-03-31	16.15
2015-12-31	19.87
2015-09-30	10.35
2015-06-30	13.19
2015-03-31	9.59
2014-12-31	12.95
2014-09-30	24.31
2014-06-30	5.01
2014-03-31	6.63
2013-12-31	5.39
2013-09-30	0.00
2013-06-30	0.00
2013-03-31	0.00

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

13.03

2026-03-31

14.73

2025-12-31

15.32

2025-09-30

7.78

2025-06-30

10.02

2025-03-31

10.14

2024-12-31

10.59

2024-09-30

12.94

2024-06-30

16.55

2024-03-31

21.29

2023-12-31

6.59

2023-09-30

3.96

2023-06-30

3.04

2023-03-31

3.53

2022-12-31

4.07

2022-09-30

4.92

2022-06-30

6.08

2022-03-31

7.23

2021-12-31

7.22

2021-09-30

8.06

2021-06-30

10.00

2021-03-31

8.27

2020-12-31

9.19

2020-09-30

3.53

2020-06-30

6.46

2020-03-31

4.86

2019-12-31

4.92

2019-09-30

6.25

2019-06-30

6.39

2019-03-31

9.16

2018-12-31

6.11

2018-09-30

4.34

2018-06-30

4.90

2018-03-31

4.89

2017-12-31

3.22

2017-09-30

4.78

2017-06-30

5.20

2017-03-31

9.61

2016-12-31

8.41

2016-09-30

9.30

2016-06-30

13.21

2016-03-31

16.15

2015-12-31

19.87

2015-09-30

10.35

2015-06-30

13.19

2015-03-31

9.59

2014-12-31

12.95

2014-09-30

24.31

2014-06-30

5.01

2014-03-31

6.63

2013-12-31

5.39

2013-09-30

0.00

2013-06-30

0.00

2013-03-31

0.00

Quick Ratio (Acid-Test): 13.03

OCUL Quick Ratio

OCUL Average Quick Ratio (Acid-Test) Chart

OCUL Current vs Average Quick Ratio (Acid-Test) Chart

OCUL Quick Ratio (Acid-Test) Metrics

OCUL Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

OCUL Quick Ratio (Acid-Test) History

Related Metrics